| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment
|
Saif, Muhammad Wasif
|
|
|
88 |
3 |
p. 485-497
|
artikel
|
| 2 |
A phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX04 to reference bevacizumab sourced from the United States, the European Union, and China in healthy Chinese male volunteers
|
Zhu, Xiaoxue
|
|
|
88 |
3 |
p. 465-474
|
artikel
|
| 3 |
A triple combination gemcitabine + romidepsin + cisplatin to effectively control triple-negative breast cancer tumor development, recurrence, and metastasis
|
Pattarawat, Pawat
|
|
|
88 |
3 |
p. 415-425
|
artikel
|
| 4 |
Correction to: PDK4 promotes tumorigenesis and cisplatin resistance in lung adenocarcinoma via transcriptional regulation of EPAS1
|
Yu, Shuo
|
|
|
88 |
3 |
p. 563
|
artikel
|
| 5 |
Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients
|
Helsby, Nuala
|
|
|
88 |
3 |
p. 533-542
|
artikel
|
| 6 |
Dabrafenib and trametinib exposure-efficacy and tolerance in metastatic melanoma patients: a pharmacokinetic–pharmacodynamic real-life study
|
Goldwirt, Lauriane
|
|
|
88 |
3 |
p. 427-437
|
artikel
|
| 7 |
Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants
|
Ogasawara, Ken
|
|
|
88 |
3 |
p. 369-377
|
artikel
|
| 8 |
Evaluation of two software using Bayesian methods for monitoring exposure and dosing once-daily intravenous busulfan in paediatric patients receiving haematopoietic stem cell transplantation
|
Lawson, Rachael
|
|
|
88 |
3 |
p. 379-391
|
artikel
|
| 9 |
Feasibility of pharmacometabolomics to identify potential predictors of paclitaxel pharmacokinetic variability
|
Chen, Li
|
|
|
88 |
3 |
p. 475-483
|
artikel
|
| 10 |
Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors
|
Pilla Reddy , Venkatesh
|
|
|
88 |
3 |
p. 451-464
|
artikel
|
| 11 |
Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure
|
Tsuboya, Ayako
|
|
|
88 |
3 |
p. 543-553
|
artikel
|
| 12 |
Molecular predictors of the outcome of paclitaxel plus carboplatin neoadjuvant therapy in high-grade serous ovarian cancer patients
|
Sokolenko, Anna P.
|
|
|
88 |
3 |
p. 439-450
|
artikel
|
| 13 |
Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression
|
Sugiu, Kazuhisa
|
|
|
88 |
3 |
p. 513-524
|
artikel
|
| 14 |
Panobinostat penetrates the blood–brain barrier and achieves effective brain concentrations in a murine model
|
Homan, Morgan J.
|
|
|
88 |
3 |
p. 555-562
|
artikel
|
| 15 |
Phase II study of trifluridine/tipiracil (TAS-102) therapy in elderly patients with colorectal cancer (T-CORE1401): geriatric assessment tools and plasma drug concentrations as possible predictive biomarkers
|
Takahashi, Masanobu
|
|
|
88 |
3 |
p. 393-402
|
artikel
|
| 16 |
Phase I study of liposomal irinotecan (LY01610) in patients with advanced esophageal squamous cell carcinoma
|
Liu, Yun
|
|
|
88 |
3 |
p. 403-414
|
artikel
|
| 17 |
Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study
|
Wang, Bei
|
|
|
88 |
3 |
p. 499-512
|
artikel
|
| 18 |
Serum and hematologic responses after three cycles of cabazitaxel therapy as predictors of survival in castration-resistant prostate cancer
|
Fujiwara, Motohiro
|
|
|
88 |
3 |
p. 525-531
|
artikel
|
Tijdschrift beschrijving